@article{104bf9ce3fa944c59a2bc264706446b4,
title = "Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia",
abstract = "Frontline arsenic trioxide (ATO)–based treatment regimens achieve high rates of long-term relapse-free survival in treating acute promyelocytic leukemia (APL) and form the current standard of care. Refining prognostic estimates for newly diagnosed patients treated with ATO-containing regimens remains important in continuing to improve outcomes and identify patients who achieve suboptimal outcomes. We performed a pooled analysis of exclusively ATO-treated patients at a single academic institution and from the ALLG APML4 and Alliance C9710 studies to determine the prognostic importance of additional cytogenetic abnormalities and/or complex karyotype. We demonstrated inferior event-free survival for patients harboring complex karyotype (hazard ratio [HR], 3.74; 95% confidence interval [CI], 1.63-8.56; P 5 .002), but not for patients harboring additional cytogenetic abnormalities (HR, 2.13; 95% CI, 0.78-5.82; P 5 .142). These data support a role for full karyotypic analysis of all patients with APL and indicate a need for novel treatment strategies to overcome the adverse effect of APL harboring complex karyotype.",
author = "Epstein-Peterson, {Zachary D.} and Andriy Derkach and Susan Geyer and Krzysztof Mr{\'o}zek and Jessica Kohlschmidt and Park, {Jae H.} and Sridevi Rajeeve and Stein, {Eytan M.} and Yanming Zhang and Harry Iland and Campbell, {Lynda J.} and Larson, {Richard A.} and Xavier Poir{\'e} and Powell, {Bayard L.} and Wendy Stock and Stone, {Richard M.} and Tallman, {Martin S.}",
note = "Funding Information: This work was supported by an institutional grant from the National Institutes of Health, National Cancer Institute (NCI) grant P30CA008748; an AACR-AstraZeneca Lymphoma Research Fellowship and support through the Lymphoma Research Foundation{\textquoteright}s Lymphoma Scientific Research Mentorship Program and the AIDS Malignancy Consortium{\textquoteright}s Domestic Scholar Program (Z.D.EP); and an institutional cancer center grant from the NCI P30 CA008748 (Z.D.E.P., A.D., Y.Z., and M.S.T.). Support for the C9710 trial was provided by a grant from the NCI to Cancer and Leukemia Group B (CALGB; CA31946; Durham, NC) and by NCI grant CA33601 to the CALGB Statistical Center. Publisher Copyright: {\textcopyright} 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.",
year = "2022",
month = jun,
day = "14",
doi = "10.1182/bloodadvances.2021006682",
language = "English (US)",
volume = "6",
pages = "3433--3439",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",
}